Nonalcoholic fatty liver disease (NAFLD) afflicts 100 million Americans, with 20% suffering from more advanced nonalcoholic steatohepatitis (NASH).1

LiverMultiScan may help clinicians identify these patients and determine a treatment pathway to turn back the clock on liver disease, reducing risk of progression, serious complications, and death. 

1

Diagnose Early

LiverMultiScan provides a high-value, noninvasive test to help identify nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) and assess disease severity.2,7 

When included in the clinical pathway for patients suspected to have fatty liver disease, LiverMultiScan can stage, risk stratify, and inform the referral decision for further evaluation and management.3

LiverMultiScan provides three key biomarkers in one single scan to aid in the assessment of NAFLD and NASH.4–7

It quantifies highly reproducible metrics (see figure 1):

  • Fibro-inflammation, measured by iron-corrected T1 (cT1)
  • Liver fat, measured by proton density fat fraction (PDFF)
  • Hepatic iron content, measured by T2*

LiverMultiScan provides quantitative data to clinicians to help improve the care of patients with suspected liver disease by quantitatively characterizing the health of the liver using multiparametric magnetic resonance imaging (mpMRI).

It is intended to aid clinicians in the diagnosis, risk stratification, treatment pathway planning, and monitoring of liver disease as part of the diagnostic pathway for NAFLD.3

LiverMultiScan provides specific, repeatable, and reliable AI digital biomarkers to advance medical care.7–9 It is standardized across MRI field strengths and major vendors making it suitable for use in most hospitals and imaging centers in the U.S. 

open image in new tab

Diagnose Early

Figure 1: Accurate and precise biomarkers for characterizing liver disease

 

2

Predict Prognosis

LiverMultiScan cT1 was shown to predict clinical outcomes in 112 chronic liver disease (CLD) patients who were followed up over a median of 27 months10 as well as in a larger cohort of 197 CLD patients over a median of 43 months, with the latter study showing a similar predictive performance to liver biopsy (see figure 1).11

LiverMultiScan cT1 can provide knowledge about the patient's liver disease stage enabling the clinician to improve treatment decisions, with the potential to prevent disease progression and improve patient outcomes.12,13

Studies have found that:

  • LiverMultiScan biomarkers, cT1 and PDFF, were correlated with histopathological hallmarks of NASH in 264 patients with body mass index (BMI) ≥ 30 kg/m2.14
  • LiverMultiScan cT1 prospectively determined the prevalence of NAFLD and NASH, based on histology, in 664 asymptomatic middle-aged Americans.2
  • LiverMultiScan cT1 accurately identified patients with NASH and high-risk NASH (defined by NAFLD activity score ≥ 4 and fibrosis ≥ 2) relative to histology, in a cohort of 54313 and 14512 participants with a suspected or historical diagnosis of NAFLD.
  • LiverMultiScan is not confounded by obesity.15
open image in new tab

Predict Prognosis

Figure 1: Kaplan-Meier plots of the percentage of chronic liver disease patients remaining event-free, stratified by cT1 > 825ms,
demonstrates how cT1 can help to predict clinical outcomes. Adapted from Jayaswal et al, 202021

3

Monitor Progress

LiverMultiScan offers state-of-the art precision imaging for patient management. It can support timely identification of patients suspected with liver disease who are at a higher risk of severe disease, and for monitoring longitudinal change in patients with NASH.3

LiverMultiScan also demonstrates excellent repeatability and reproducibility, making it suitable for follow-up and monitoring change in chronic liver disease.9

LiverMultiScan is sensitive to treatment response, as well as to histopathological response8,16,17, in line with the NAFLD activity score (NAS).16  

cT1 has been shown to detect changes in as early as six weeks (early treatment response) that correlated with the histological response (see figure 1).

cT1 has also shown meaningful response to treatment.17 (see figure 2)

open image in new tab

Monitor Progress

Figure 1: In NGM-282 Phase 2 study16, changes were observed in LiverMultiScan cT1 images over 12 weeks (top) and corresponding histology (bottom)

open image in new tab

Monitor Progress

Figure 2: In the early-phase study of a novel NASH treatment, AXA1125, cT1 showed a significant response to treatment after 16 weeks.